References
- Angus DC. (2012). The acute respiratory distress syndrome: what’s in a name? JAMA 307:2542–4.
- Ashbaugh DG, Bigelow DB, Petty TL, et al. (2005). Acute respiratory distress in adults. The Lancet, Saturday 12 August 1967. Crit Care Resusc 7:60–1.
- Bernard GR, Artigas A, Brigham KL, et al. (1994). The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818–24.
- Buregeya E, Fowler RA, Talmor DS, et al. (2014). Acute respiratory distress syndrome in the global context. Glob Heart 9:289–95.
- Chen XY, Wang SM, Li N, et al. (2013). Creation of lung-targeted dexamethasone immunoliposome and its therapeutic effect on bleomycin-induced lung injury in rats. PLoS One 8:e58275.
- Courrier HM, Butz N, Vandamme TF. (2002). Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst 19:425–98.
- Curtis JR, Westfall AO, Allison J, et al. (2006). Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55:420–6.
- Dandekar P, Venkataraman C, Mehra A. (2010). Pulmonary targeting of nanoparticle drug matrices. J Aerosol Med Pulmon Drug Deliv 23:343–53.
- Desmyter A, Spinelli S, Roussel A, Cambillau C. (2015). Camelid nanobodies: killing two birds with one stone. Curr Opin Struct Biol 32:1–8.
- Ferguson ND, Kacmarek RM, Chiche JD, et al. (2004). Screening of ARDS patients using standardized ventilator settings: influence on enrollment in a clinical trial. Intensive Care Med 30:1111–16.
- Gajic O, Dabbagh O, Park PK, et al. (2011). Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score. Am J Respir Crit Care Med 183:462–70.
- Greenstein S, Ghias K, Krett NL, Rosen ST. (2002). Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 8:1681–94.
- Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. (1993). Naturally occurring antibodies devoid of light chains. Nature 363:446–8.
- Irwin RS, Richardson ND. (2006). Side effects with inhaled corticosteroids: the physician’s perception. Chest 130:41S–53S.
- Maybauer MO, Maybauer DM, Herndon DN. (2006). Incidence and outcomes of acute lung injury. N Engl J Med 354:416–17.
- Mikawa K, Nishina K, Takao Y, Obara H. (2003). ONO-1714, a nitric oxide synthase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits. Anesth Analg 97:1751–5.
- Pan D, Lanza GM, Wickline SA, Caruthers SD. (2009). Nanomedicine: perspective and promises with ligand-directed molecular imaging. Eur J Radiol 70:274–85.
- Ranieri VM, Rubenfeld GD, Thompson BT, et al. (2012). Acute respiratory distress syndrome: the Berlin Definition. JAMA 307:2526–33.
- Rochat TS, Janssens JP. (2012). Systemic and oropharyngeal side effects of inhaled corticosteroids. Rev Med Suisse 8:2219–23.
- Schmiedl A, Ochs M, Muhlfeld C, et al. (2005). Distribution of surfactant proteins in type II pneumocytes of newborn, 14-day old, and adult rats: an immunoelectron microscopic and stereological study. Histochem Cell Biol 124:465–76.
- Siontorou CG. (2013). Nanobodies as novel agents for disease diagnosis and therapy. Int J Nanomedicine 8:4215–27.
- Thompson BT, Matthay MA. (2013). The Berlin definition of ARDS versus pathological evidence of diffuse alveolar damage. Am J Respir Crit Care Med 187:675–7.
- Wang SM, He X, Li N, et al. (2015). A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting. Int J Nanomedicine 10:2857–69.
- Warrington TP, Bostwick JM. (2006). Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 81:1361–7.
- Wyss C, Schaefer SC, Juillerat-Jeanneret L, et al. (2009). Molecular imaging by micro-CT: specific E-selectin imaging. Eur Radiol 19:2487–94.
- Zhai J, Scoble JA, Li N, et al. (2015). Epidermal growth factor receptor-targeted lipid nanoparticles retain self-assembled nanostructures and provide high specificity. Nanoscale 7:2905–13.